GlassScriptPhysician profile
Murray Matthew Arons
NPI 1801894142
$14,544.71
in general payments reported to CMS, 2019-2025
40 companies · $8,152 in 2025
The $8,152 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $752 · 2021: $1,024 · 2022: $1,306 · 2023: $1,423 · 2024: $815 · 2025: $8,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,100 · Food and Beverage: $2,312 · Travel and Lodging: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,099.99 |
| Food and Beverage | $2,312.11 |
| Travel and Lodging | $978.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,007.10 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $1,733.96 | 2019-2024 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $793.25 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Insmed, INC. | $614.04 | 2019-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.84 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Inspire Medical Systems, INC. | $331.46 | 2023-2024 | Inspire |
| Jazz Pharmaceuticals INC. | $290.07 | 2019-2024 | Xywav |
| Grifols USA, LLC | $272.65 | 2019-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $218.88 | 2019-2025 | Winrevair, Keytruda, Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $205.13 | 2019-2024 | Airsupra, Fasenra |
| Harmony Biosciences LLC | $164.08 | 2021-2024 | Wakix |
| Genzyme Corporation | $123.22 | 2020-2024 | |
| Medtronic, INC. | $105.41 | 2024 | Arcpoint |
| Novartis Pharmaceuticals Corporation | $100.00 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $96.90 | 2021-2024 | Dupixent |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murray Arons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.